Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the second-costliest quintile among peers.
Lazard Managed Equity Volatility Open MEVOX
- NAV / 1-Day Return 12.62 / +0.24 %
- Total Assets 17.0 Mil
-
Adj. Expense Ratio
- Expense Ratio 1.000%
- Distribution Fee Level Average
- Share Class Type No Load
- Category Global Large-Stock Blend
- Investment Style Large Blend
- Min. Initial Investment 2,500
- Status Open
- TTM Yield 2.38%
- Turnover 83%
USD | NAV as of Apr 19, 2024 | 1-Day Return as of Apr 19, 2024, 10:18 PM GMT+0
Morningstar’s Analysis MEVOX
Will MEVOX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 14.4
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Bristol-Myers Squibb Co | 1.58 | 284,057 | Healthcare |
Colgate-Palmolive Co | 1.54 | 276,634 | Consumer Defensive |
NewMarket Corp | 1.50 | 269,714 | Basic Materials |
Gilead Sciences Inc | 1.48 | 265,751 | Healthcare |
Procter & Gamble Co | 1.44 | 259,762 | Consumer Defensive |
Kimberly-Clark Corp | 1.42 | 256,242 | Consumer Defensive |
Roche Holding AG | 1.41 | 253,235 | Healthcare |
PepsiCo Inc | 1.34 | 240,989 | Consumer Defensive |
Japan Post Holdings Co Ltd | 1.33 | 239,574 | Financial Services |
Merck & Co Inc | 1.31 | 235,003 | Healthcare |